|
Match
|
Document |
Document Title |
|
|
US20090275597 |
METHODS OF TREATING CNS DISORDERS
The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with...
|
|
|
US20090253803 |
MEMANTINE PROTECTS INFLAMMATION-RELATED DEGENERATION OF DOPAMINE NEURONS THROUGH INHIBITION OF OVER-ACTIVATED MICROGLIA AND RELEASE OF NEUROTROPHIC FACTORS FROM ASTROGLIA
This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA...
|
|
|
US20090253728 |
Methods and Compositions for Treating Nociceptive Pain
The present invention provides methods and compositions useful for the treatment and prevention of pain.
|
|
|
US20090252704 |
THERAPIES FOR COGNITION AND LEARNING ENHANCEMENT
The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as...
|
|
|
US20090247644 |
MEMANTINE FORMULATIONS
The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to...
|
|
|
US20090234021 |
Treatment of Demyelinating Conditions
The present invention provides novel methods and compositions for the treatment of multiple sclerosis.
|
|
|
US20090221627 |
Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
Some exemplary embodiments comprise fluoro-containing derivatives of pyrido[4,3-b]indoles (and exemplary methods of making the same) that may be administered to a mammal (including a human) in an...
|
|
|
US20090220516 |
Neuroprotection of retinal ganglion cells
This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing...
|
|
|
US20090202597 |
Ache-Nmda Combination Wafer
Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form...
|
|
|
US20090186107 |
Orally Administrable Films and Preparation Thereof
The invention relates to an orally administrable mucoadhesive film which comprises one or more bioactive ingredients and, as a major film-forming polymer, at least one alginate which is capable of...
|
|
|
US20090169511 |
Mucosal Bioadhesive SLow Release Carrier for Delivering Active Principles
A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This...
|
|
|
US20090118376 |
Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA...
|
|
|
US20090088367 |
Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's...
|
|
|
US20090042823 |
USES OF BROAD SPECTRUM RNAI THERAPEUTICS AGAINST INFLUENZA
Methods and uses of RNAi-inducing agents for medicaments and treating or preventing a viral infection.
|
|
|
US20090041820 |
Functional polymer compositions
Functional polymer compositions and methods of forming such compositions are provided. The functional polymer compositions include at least 50 wt % of one or more polymer components; from 0.1 to 50...
|
|
|
US20090023778 |
Composition Containing Anti-Dementia Drug
An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a...
|
|
|
US20090005459 |
NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated...
|
|
|
US20080299197 |
Triple Combination Release Multi-Layered Tablet
This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( 1...
|
|
|
US20080279819 |
Combinations Therapy for Treatment of Demyelinating Conditions
The present invention provides novel methods and compositions for the treatment and prevention of demyelinating conditions. One demyelinating condition treated by the methods and compositions of...
|
|
|
US20080275112 |
Invention Concerning Aminoadamantane Compounds
The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally...
|
|
|
US20080261985 |
SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES)
This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The...
|
|
|
US20080199458 |
INFLUENZA PREVENTION AND TREATMENT COMPOSITION
A composition for influenza treatment includes an immune enhancer and an anti-viral agent
|
|
|
US20080194698 |
Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders
The present invention provides for the use of an NMDA receptor antagonist, preferably memantine or neramexane or a pharmaceutical acceptable salt or a prodrug of said antagonists, in the...
|
|
|
US20080193503 |
MEMANTINE INTRAVITREAL IMPLANTS
Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended...
|
|
|
US20080193502 |
MEMANTINE INTRAVITREAL IMPLANTS
Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended...
|
|
|
US20080038200 |
MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION
The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate...
|
|
|
US20080033054 |
Process for preparing memantine hydrochloride substantially free of impurities
The present invention encompasses processes for preparing Memantine hydrochloride and its derivatives, substantially free of impurities.
|
|
|
US20080033053 |
Cross-Reference To Related Applications
Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.
|
|
|
US20080008743 |
Orally Dissolving Formulations of Memantine
Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by...
|